ATG5 and triple-A syndrome: In fact, angiotensin II‐treated Atg5‐deficient mice with TGF‐β inhibition showed a higher incidence and greater severity of AAA than angiotensin II infused Atg7‐deficient mice without TGF‐β inhibition.